↓ Skip to main content

Dove Medical Press

Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma

Overview of attention for article published in Journal of Hepatocellular Carcinoma, May 2021
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#28 of 260)
  • Good Attention Score compared to outputs of the same age (69th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter
2 X users
patent
1 patent
video
1 YouTube creator

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
14 Mendeley
Title
Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma
Published in
Journal of Hepatocellular Carcinoma, May 2021
DOI 10.2147/jhc.s304275
Pubmed ID
Authors

Nadine Abi-Jaoudeh, Farshid Dayyani, Pei Jer Chen, Dayantha Fernando, Nicholas Fidelman, Hanna Javan, Po-Chin Liang, Jen-I Hwang, David K Imagawa

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 21%
Student > Postgraduate 1 7%
Student > Doctoral Student 1 7%
Unknown 9 64%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 21%
Agricultural and Biological Sciences 1 7%
Medicine and Dentistry 1 7%
Unknown 9 64%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 December 2022.
All research outputs
#6,502,992
of 25,220,525 outputs
Outputs from Journal of Hepatocellular Carcinoma
#28
of 260 outputs
Outputs of similar age
#130,313
of 434,620 outputs
Outputs of similar age from Journal of Hepatocellular Carcinoma
#4
of 23 outputs
Altmetric has tracked 25,220,525 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 260 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 434,620 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.